Quick answers
- What is Azelastine hydrochloride and fluticasone propionate used for?
- The FDA-approved label (Azelastine Hydrochloride and Fluticasone Propionate, Mylan Pharmaceuticals Inc., December 15, 2024) says: “Azelastine hydrochloride and fluticasone propionate nasal spray is indicated for the relief of symptoms of seasonal allergic rhinitis in adult and pediatric patients 6 years of age and older. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- What are the side effects of Azelastine hydrochloride and fluticasone propionate?
- The “Adverse Reactions” section of the FDA label (Azelastine Hydrochloride and Fluticasone Propionate, Mylan Pharmaceuticals Inc., December 15, 2024) begins: “The following clinically significant adverse reactions are described elsewhere in the labeling: • Somnolence [see Warnings and Precautions (5.1)] • Local nasal effects, including epistaxis, nasal ulceration, nasal septal perforation, impaired wound healing, and Candida albicans infection [see Warnings and Precautions (5.2)] • Glaucoma and Cataracts [see Warnings and Precautions (5.3)] • Immunosuppression and Risk of Infections [see Warnings and Precautions (5.4)] • Hypercorticism and Adrenal Suppression, including growth reduction [see Warnings and Precautions (5.5 and 5.7), Use in Specific Populations (8.4)] The most common adverse reactions (≥ 2% incidence) are: dysgeusia, epistaxis, and headache.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- What are the drug interactions of Azelastine hydrochloride and fluticasone propionate?
- The “Drug Interactions” section of the FDA label (Azelastine Hydrochloride and Fluticasone Propionate, Mylan Pharmaceuticals Inc., December 15, 2024) begins: “No formal drug interaction studies have been performed with azelastine hydrochloride and fluticasone propionate nasal spray. The drug interactions of the combination are expected to reflect those of the individual components. • Potent inhibitors of cytochrome P450 (CYP) 3A4: May increase blood levels of fluticasone propionate. • Ritonavir: Coadministration is not recommended. (5.6, 7.2) • Other potent CYP3A4 inhibitors, such as ketoconazole: use caution with coadministration.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Azelastine hydrochloride and fluticasone propionate have a boxed warning?
- No. None of the 7 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Azelastine hydrochloride and fluticasone propionate?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from November 13, 2026).
- Has Azelastine hydrochloride and fluticasone propionate been recalled?
- FDA enforcement reports list 2 recalls of products of this medicine; the newest started February 1, 2019 (Class II). A recall usually concerns specific lots, not every product.
- Who makes Azelastine hydrochloride and fluticasone propionate?
- 6 companies list prescription products of Azelastine hydrochloride and fluticasone propionate in the FDA NDC Directory, including Bryant Ranch Prepack, Mylan Pharmaceuticals Inc. and Padagis Israel Pharmaceuticals Ltd.
What Azelastine hydrochloride and fluticasone propionate is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
Azelastine hydrochloride and fluticasone propionate nasal spray is indicated for the relief of symptoms of seasonal allergic rhinitis in adult and pediatric patients 6 years of age and older. …
— FDA label: Azelastine Hydrochloride and Fluticasone Propionate, Mylan Pharmaceuticals Inc., effective December 15, 2024. Read the full label on DailyMed →
Label quoted: the one for the most common form (spray, metered, nasal), Azelastine Hydrochloride and Fluticasone Propionate, Mylan Pharmaceuticals Inc.; it covers 1 product in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.
The FDA has 7 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 7 FDA labels for this medicine have a boxed warning.
Azelastine hydrochloride and fluticasone propionate side effects
Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.
The following clinically significant adverse reactions are described elsewhere in the labeling:
- Somnolence [see Warnings and Precautions (5.1)]
- Local nasal effects, including epistaxis, nasal ulceration, nasal septal perforation, impaired wound healing, and Candida albicans infection [see Warnings and Precautions (5.2)]
- Glaucoma and Cataracts [see Warnings and Precautions (5.3)]
- Immunosuppression and Risk of Infections [see Warnings and Precautions (5.4)]
- Hypercorticism and Adrenal Suppression, including growth reduction [see Warnings and Precautions (5.5 and 5.7), Use in Specific Populations (8.4)] The most common adverse reactions (≥ 2% incidence) are: dysgeusia, epistaxis, and headache.
Read more of this section
(6.1) To report SUSPECTED ADVERSE REACTIONS, contact Mylan at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect rates observed in practice. Adults and Adolescents 12 Years of Age and Older The safety data described below in adults and adolescents 12 years of age and older reflect exposure to azelastine hydrochloride and fluticasone propionate nasal spray in 853 patients (12 years of age and older; 36% male and 64% female) with seasonal allergic rhinitis in 3 double-blind, placebo-controlled clinical trials of 2-week duration. The racial distribution for the 3 clinical trials was 80% white, 16% black, 2% Asian, and 1% other. In the 3 placebo controlled clinical trials of 2-week duration, 3411 patients with seasonal allergic rhinitis were treated with 1 spray per nostril of azelastine hydrochloride and fluticasone propionate nasal spray, azelastine hydrochloride nasal spray, fluticasone propionate nasal spray, or placebo, twice daily. The azelastine hydrochloride and fluticasone propionate comparators use the same vehicle and device as azelastine hydrochloride and fluticasone propionate nasal spray and are not commercially marketed. Overall, adverse reactions were 16% in the azelastine hydrochloride and fluticasone propionate nasal spray treatment groups, 15% in the azelastine hydrochloride nasal spray groups, 13% in the fluticasone propionate nasal spray groups, and 12% in the placebo groups. Overall, 1% of patients in both the azelastine hydrochloride and fluticasone propionate nasal spray and placebo groups discontinued due to adverse reactions. Table 1 contains adverse reactions reported with frequencies greater than or equal to 2% and more frequently than placebo in patients treated with azelastine hydrochloride and fluticasone propionate nasal spray in the seasonal allergic rhinitis controlled clinical trials. Table 1.
Table from the label
| 1 spray per nostril twice daily | ||||
|---|---|---|---|---|
| Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray(N = 853)Safety population N = 853, intent-to-treat population N = 848 | Azelastine Hydrochloride Nasal SprayNot commercially marketed (N = 851) | Fluticasone Propionate Nasal Spray(N = 846) | Vehicle Placebo(N = 861) | |
| Dysgeusia | 30 (4%) | 44 (5%) | 4 (1%) | 2 (< 1%) |
| Headache | 18 (2%) | 20 (2%) | 20 (2%) | 10 (1%) |
| Epistaxis | 16 (2%) | 14 (2%) | 14 (2%) | 15 (2%) |
— FDA label: Azelastine Hydrochloride and Fluticasone Propionate, Mylan Pharmaceuticals Inc., effective December 15, 2024. This is part of the section. Read the full label on DailyMed →
Azelastine hydrochloride and fluticasone propionate drug interactions
Quoted from the “Drug Interactions” section of the FDA-approved label. Tell your pharmacist about every medicine, vitamin and herbal product you take.
No formal drug interaction studies have been performed with azelastine hydrochloride and fluticasone propionate nasal spray. The drug interactions of the combination are expected to reflect those of the individual components.
- Potent inhibitors of cytochrome P450 (CYP) 3A4: May increase blood levels of fluticasone propionate.
- Ritonavir: Coadministration is not recommended. (5.6, 7.2)
- Other potent CYP3A4 inhibitors, such as ketoconazole: use caution with coadministration.
Read more of this section
(5.6, 7.2) 7.1 Central Nervous System Depressants Concurrent use of azelastine hydrochloride and fluticasone propionate nasal spray with alcohol or other central nervous system depressants should be avoided because somnolence and impairment of central nervous system performance may occur [see Warnings and Precautions (5.1)]. 7.2 Cytochrome P450 3A4 Ritonavir (a strong CYP3A4 inhibitor) significantly increased plasma fluticasone propionate exposure following administration of fluticasone propionate aqueous nasal spray, resulting in significantly reduced serum cortisol concentrations [see Clinical Pharmacology (12.3)]. During postmarketing use, there have been reports of clinically significant drug interactions in patients receiving fluticasone propionate and ritonavir, resulting in systemic corticosteroid effects including Cushing syndrome and adrenal suppression. Therefore, coadministration of fluticasone propionate and ritonavir is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects. Ketoconazole (also a strong CYP3A4 inhibitor), administered in multiple 200 mg doses to steady-state, increased plasma exposure of fluticasone propionate, reduced plasma cortisol AUC, but had no effect on urinary excretion of cortisol, following administration of a single 1000 mcg dose of fluticasone propionate by oral inhalation route. Caution should be exercised when azelastine hydrochloride and fluticasone propionate nasal spray is coadministered with ketoconazole and other known strong CYP3A4 inhibitors.
— FDA label: Azelastine Hydrochloride and Fluticasone Propionate, Mylan Pharmaceuticals Inc., effective December 15, 2024. Read the full label on DailyMed →
Azelastine hydrochloride and fluticasone propionate dosage
Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.
- Recommended dosage: 1 spray per nostril twice daily (2.1)
- For nasal use only. (2.2)
- Prime before initial use and when it has not been used for 14 or more days.
Read more of this section
(2.2) 2.1 Recommended Dosage The recommended dosage of azelastine hydrochloride and fluticasone propionate nasal spray is 1 spray (137 mcg of azelastine hydrochloride and 50 mcg of fluticasone propionate) in each nostril twice daily. 2.2 Important Administration Instructions
- Administer azelastine hydrochloride and fluticasone propionate nasal spray by the nasal route only.
- Shake the bottle gently before each use.
- Avoid spraying azelastine hydrochloride and fluticasone propionate nasal spray into the eyes. If sprayed in the eyes, flush eyes with water for at least 10 minutes. Priming Prime azelastine hydrochloride and fluticasone propionate nasal spray before initial use by releasing 6 sprays or until a fine mist appears. Repriming (as needed) When azelastine hydrochloride and fluticasone propionate nasal spray has not been used for 14 or more days, reprime with 1 spray or until a fine mist appears.
— FDA label: Azelastine Hydrochloride and Fluticasone Propionate, Mylan Pharmaceuticals Inc., effective December 15, 2024. Read the full label on DailyMed →
Azelastine hydrochloride and fluticasone propionate in pregnancy
Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.
Risk Summary Limited data from postmarketing experience with azelastine hydrochloride and fluticasone propionate nasal spray in pregnant women have not identified any drug associated risks of miscarriage, birth defects, or other adverse maternal or fetal outcomes. The individual components of azelastine hydrochloride and fluticasone propionate nasal spray have been marketed for decades.
Read more of this section
While the data regarding the use of nasal preparations of fluticasone propionate in pregnancy are limited, data from clinical studies of inhaled fluticasone propionate do not indicate an increased risk of adverse maternal or fetal outcomes. Animal reproduction studies with azelastine hydrochloride and fluticasone propionate nasal spray are not available; however, studies are available with its individual components, azelastine hydrochloride and fluticasone propionate. In animal reproduction studies, there was no evidence of fetal harm in animals at oral doses of azelastine hydrochloride approximately 10 times the clinical daily dose. Oral administration of azelastine hydrochloride to pregnant mice, rats, and rabbits, during the period of organogenesis, produced developmental toxicity that included structural abnormalities, decreased embryo-fetal survival, and decreased fetal body weights at doses 530 times and higher than the maximum recommended human daily nasal dose (MRHDID) of 0.548 mg. However, the relevance of these findings in animals to pregnant women was considered questionable based upon the high animal to human dose multiple. In animal reproduction studies, fluticasone propionate administered via nose-only inhalation to rats decreased fetal body weight, but did not induce teratogenicity at a maternal toxic dose less than the MRHDID on a mcg/m 2 basis. Teratogenicity, characteristic of corticosteroids, decreased fetal body weight and/or skeletal variations, in rats, mice, and rabbits were observed with subcutaneously administered maternal toxic doses of fluticasone propionate less than the MRHDID of 200 mcg on a mcg/m 2 basis (see Data). Experience with corticosteroids suggests that rodents are more prone to teratogenic effects from corticosteroids than humans. The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Data Animal Data Azelastine Hydrochloride In an embryo-fetal development study in mice dosed during the period of organogenesis, azelastine hydrochloride caused embryo-fetal death, structural abnormalities (cleft palate; short or absent tail; fused, absent or branched ribs), delayed ossification, and decreased fetal weight at approximately 610 times the MRHDID in adults (on a mg/m 2 basis at a maternal oral dose of 68.6 mg/kg/day), which also caused maternal toxicity as evidenced by decreased maternal body weight.
— FDA label: Azelastine Hydrochloride and Fluticasone Propionate, Mylan Pharmaceuticals Inc., effective December 15, 2024. This is part of the section. Read the full label on DailyMed →
When Azelastine hydrochloride and fluticasone propionate should not be used
Quoted from the “Contraindications” section of the FDA-approved label.
Azelastine hydrochloride and fluticasone propionate nasal spray is contraindicated in patients with hypersensitivity to azelastine hydrochloride, fluticasone propionate, or to any other ingredients of azelastine hydrochloride and fluticasone propionate nasal spray. Reactions have included anaphylaxis [see Adverse Reactions (6.2)].
Read more of this section
Hypersensitivity to azelastine hydrochloride, fluticasone propionate, or to any ingredients of azelastine hydrochloride and fluticasone propionate nasal spray. Reactions have included anaphylaxis. (4)
— FDA label: Azelastine Hydrochloride and Fluticasone Propionate, Mylan Pharmaceuticals Inc., effective December 15, 2024. Read the full label on DailyMed →
Azelastine hydrochloride and fluticasone propionate overdose
Quoted from the “Overdosage” section of the FDA-approved label. If someone may have taken too much, call Poison Help at 1-800-222-1222 (or 911 in an emergency).
Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray: Azelastine hydrochloride and fluticasone propionate nasal spray contains both azelastine hydrochloride and fluticasone propionate; therefore, the risks associated with overdosage for the individual components described below apply to azelastine hydrochloride and fluticasone propionate nasal spray. Azelastine Hydrochloride: There have been no reported overdosages with azelastine hydrochloride.
Read more of this section
Acute azelastine hydrochloride overdosage by adults with this dosage form is unlikely to result in clinically significant adverse reactions, other than increased somnolence, since one (1) 23 g bottle of azelastine hydrochloride and fluticasone propionate nasal spray contains approximately 23 mg of azelastine hydrochloride. General supportive measures should be employed if overdosage occurs. There is no known antidote to azelastine hydrochloride and fluticasone propionate nasal spray. Oral ingestion of antihistamines has the potential to cause serious adverse effects in children. Accordingly, azelastine hydrochloride and fluticasone propionate nasal spray should be kept out of the reach of children. Fluticasone Propionate: Chronic fluticasone propionate overdosage may result in signs/symptoms of hypercorticism [see Warnings and Precautions (5.5)].
— FDA label: Azelastine Hydrochloride and Fluticasone Propionate, Mylan Pharmaceuticals Inc., effective December 15, 2024. Read the full label on DailyMed →
Forms and how it is given
| Dosage forms | Spray, metered |
|---|---|
| Route | Nasal |
| Prescription products | 7 in the FDA NDC Directory |
| Brand names | Dymista |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| azelastine hydrochloride 137 ug · fluticasone propionate 50 ug spray, metered | Generic | $2.07 per gram |
| azelastine hydrochloride 137 ug · fluticasone propionate 50 ug spray, metered | Brand: Dymista | $9.10 per gram |
NADAC list of November 11, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Bryant Ranch Prepack2 products
- Mylan Pharmaceuticals Inc.1 product
- Padagis Israel Pharmaceuticals Ltd1 product
- Teva Pharmaceuticals, Inc.1 product
- Apotex Corp.1 product
- Viatris Specialty LLC1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA202236 DYMISTA | Mylan Speciality LP | May 1, 2012 | 11, latest December 17, 2024 2024: Labeling · 2021: Labeling · 2018: Labeling |
Generic approvals (3)
- ANDA207712Apotex · April 28, 2017
- ANDA208111Padagis Israel · February 18, 2021
- ANDA208436Teva Pharms USA Inc · April 8, 2025
Shortage status
The FDA drug shortage list does not show these products.
Recalls
From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
February 1, 2019 · Class II · Terminated · D-0424-2019
Defective Container: Potential for broken glass in the neck area of the glass bottles.
Dymista (azelastine hydrochloride and fluticasone propionate) Nasal Spray, 137 mcg/50 mcg per spray, 120 Metered Sprays, 23 g net fill weight bottle, Rx Only, Manufactured by: Cipla Ltd., Goa, India, M.L. No. 546; For: M — Mylan Pharmaceuticals Inc.
-
July 25, 2018 · Class II · Terminated · D-1075-2018
Presence of foreign substance: Potential for glass in the neck area of the glass bottles.
Dymista (azelastine hydrochloride and fluticasone propionate) Nasal Spray, 137 mcg / 50 mcg per spray, packaged in a 23 g net fill weight, Rx only, Manufactured by: Cipla Ltd., Goa, India, M.L.,, NDC 0037-0245-23 — Mylan Pharmaceuticals Inc.
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Official identifiers
| RxCUI (RxNorm) | 1797847, 1797849 |
|---|---|
| SPL set ID of the quoted label | 7b5cc5a0-0d47-46b5-b5fb-eb9cc248ae9e |
| FDA labels (SPL) | 7 |
| FDA applications | NDA202236, 3 ANDA |
| Active ingredients (FDA) | AZELASTINE HYDROCHLORIDE / FLUTICASONE PROPIONATE |
Next steps
- Find a pharmacy near youAsk which price applies to you and whether your product is affected by a recall
- Latest FDA drug recallsAll medicines, newest first
- DymistaBrand page: products, maker and price
- Bryant Ranch PrepackMaker or distributor
- Mylan Pharmaceuticals Inc.Maker or distributor
- Padagis Israel Pharmaceuticals LtdMaker or distributor
- All prescription drugs A to ZSearch by generic, brand or Spanish name
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Azelastine Hydrochloride and Fluticasone Propionate, Mylan Pharmaceuticals Inc., effective December 15, 2024; via openFDA, FDA data exported November 13, 2026, retrieved November 14, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →